Proteros and University of Cincinnati, Drug Discovery Center establish collaboration to offer high-throughput screening services and access to a 340,000+ compound library

Martinsried, Germany, March 09, 2011. Proteros Biostructures GmbH (Proteros) announced today that it has entered into an agreement with University of Cincinnati, Drug Discovery Center (UC DDC), under which Proteros will provide biotech and pharmaceutical companies with access to UC DDC’s ultra-high-throughput and high-content screening platform coupled with a 340,000-plus library of drug-like compounds. Proteros will be responsible for all the client interactions and project management providing a single point of contact.

Proteros now offers a comprehensive range of services for drug discovery from its own integrated lead discovery platform that includes a 30,000 member proprietary compound and fragment library, innovative kinetic and thermodynamic HTS assay technologies and structure guided medicinal chemistry to a traditional high-throughput screening approach. The structure guided approach is particularly suited to kinase targets, epigenetics targets and protein- protein interactions.

Cony D’Cruz Chief Business Officer and President Proteros US, Inc. stated, “We are very pleased to be able to offer this broad collection of discovery services to meet the diverse target and project needs of our clients. Proteros continues to enhance its service offering to enable our clients to improve the quality and productivity of their discovery efforts.”

“This powerful academic-industry collaboration in translational research combines leading capabilities at the UC DDC with Proteros’ proven technical and commercial expertise in providing discovery services and will continue to expand our base of pharmaceutical and biotechnology clients” said Dr. Ruben Papoian, Director, UC DDC.

About Proteros:
Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and fragment-based lead generation incorporating protein structure inspired compound and fragment libraries. The platform enables ‘knowledge driven lead engineering’ to accelerate and improve protein structure analysis and structure-based drug discovery. Proteros complements its clients’ internal capabilities with external expertise and access to flexible resources. Proteros currently provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Japan. Proteros US, Inc. is a wholly owned subsidiary of Proteros established to serve the growing customer base in North America.

About UC DDC:
The Drug Discovery Center at the University of Cincinnati is dedicated to the discovery and early development of novel and commercially viable therapeutic entities. The Drug Discovery Center is designed to fulfill both scientific and commercial objectives. Since becoming fully operational in mid-2006, the center has served academic, nonprofit and for-profit biomedical research organizations throughout the United States and Europe. To date, the Drug Discovery Center has run over 50 individual projects from 25 different academic, industrial and federal partners using more than1 million compounds.

Proteros biostructures GmbH
Kurt Herrenknecht, Ph.D.
Am Klopferspitz 19
82152 Martinsried
Germany
Phone: +49 (0) 89 7007 61 0
E-Mail: herrenknecht@proteros.com
Internet: www.proteros.com

Drug Discovery Center
University of Cincinnati
Ruben Papoian, Ph.D.
Director, Drug Discovery Center
University of Cincinnati
2180 E. Galbraith Road, D243
Cincinnati, Ohio 45237
Phone: +1 513 558 0516
Email: ruben.papoian@uc.edu
Internet: www.drugdiscovery.uc.edu

This release was published on openPR.